BHAVYADHARSHINI ARUN^1,#, PRARTHANA GOPINATH^1,2,#, ANUP JHA^1,3, NISHTHA TRIPATHI¹, SYED G DASTAGER^4,*, SYED K HASAN^1,3,*

Oncology Research, Vol.33, No.8, pp. 2161-2174, 2025, DOI:10.32604/or.2025.062951 - 18 July 2025

Abstract Background: Acute Myeloid Leukemia (AML) is a highly aggressive clonal hematological malignancy with limited treatment options. This study aimed to evaluate the therapeutic potential of nigericin, a polyether ionophore derived from Streptomyces DASNCL-29, as a mitochondrial-targeted agent for AML treatment. Methods: Nigericin was isolated from Streptomyces DASNCL-29 and characterized via chromatography and NMR. Its cytotoxicity was tested in MOLM13 (sensitive and venetoclax-resistant) and HL60 (sensitive and cytarabine-resistant) cells using the MTT assay. Mitochondrial dysfunction was assessed by measuring reactive oxygen species (ROS), mitochondrial membrane potential (Δψm), and mitochondrial mass. Apoptosis was evaluated with Annexin V/PI assays… More > Graphic Abstract

XINGBO WU, DAN PAN, SHOUYI TANG, YINGQIANG SHEN^*

BIOCELL, Vol.47, No.7, pp. 1459-1472, 2023, DOI:10.32604/biocell.2023.028790 - 21 June 2023

Abstract The term “undruggable” is to describe molecules that are not targetable or at least hard to target pharmacologically. Unfortunately, some targets with potent oncogenic activity fall into this category, and currently little is known about how to solve this problem, which largely hampered drug research on human cancers. Ras, as one of the most common oncogenes, was previously considered “undruggable”, but in recent years, a few small molecules like Sotorasib (AMG-510) have emerged and proved their targeted anti-cancer effects. Further, myc, as one of the most studied oncogenes, and tp53, being the most common tumor suppressor genes,… More >

Tom Pickles¹, Alan Pollack²

Canadian Journal of Urology, Vol.13, Suppl.2, pp. 68-71, 2006

Abstract Patients with intermediate-risk prostate cancer have a significant risk of biochemical failure after treatment with external beam radiation therapy. Two strategies to improve outcomes are radiation dose escalation and androgen deprivation therapy (ADT). This article discusses the evidence in favor of dose escalation.
The case for radiation dose escalation has been established by several randomized studies, which show improved biochemical control (bNED) rates. Although late toxicity was also increased, it remains at clinically acceptable levels. The use of more focal methods of radiation, such as proton therapy and intensity modulated radiation therapy (IMRT), allows safe dose More >